Sun Pharma Announces Launch of Generic Glumetza® Tablets in US

Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com Registered Office : SPARC, Tandalja, Vadodara – 390 012. India FOR IMMEDIATE RELEASE Sun Pharma Announces Launch of Generic Glumetza ® Tablets in US Mumbai, India, July 25, 2018 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN .BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has launched the generic versions of Glumetza ® (metformin hydrochloride) extended release tablets, 500 mg and 1000 mg in the US. These generic Metformin HCl extended release tablets, 500mg and 1000mg are therapeutic equivalents of Santarus Inc.’s Glumetza ® HCl extended release tablets, 500 mg and 1000 mg. The addressable market size is approximately US$ 443 million for the 12 months ending April 2018, as per IQVIA. ® - All brand names and trademarks are the property of respective owners. Disclaimer: Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looki ng statements” within the meaning of applicable sec urities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's fifth largest specialty g eneric pharmaceutical company and India's top pharm aceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is s upported by 41 manufacturing facilities spread acro ss 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the company enjoys leadership across 13 different classes of doctors with 32 bran ds featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 3 global markets. I ts API business footprint is strengthened through 1 4 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of approximately 8% of annual revenues. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live. Contacts: Sun Pharma Investors: Media: Nimish Desai Gaurav Chugh Tel +91 22 4324 4324, Xtn 2778 Tel +91 22 4324 432 4, Xtn 5373 Tel Direct +91 22 4324 2778 Tel Direct +91 22 4324 5373 Mobile +91-98203 30182 Mobile +91 98104 71414 E mail [email protected] E mail gaurav.ch [email protected]

The release as fetched from its publisher. sunpharma.com ↗